About This Fund
LAV Fund VII is a $547 million venture capital fund managed by Lilly Asia Ventures (LAV), a biomedical investment firm with offices in Shanghai, Hong Kong, and Palo Alto. The fund reached its hard cap in April 2025 and is structured as a Cayman Islands limited partnership.
LAV Fund VII continues LAV's mission to support companies developing breakthrough products that treat diseases and improve human health. The fund targets early- to growth-stage investments in biopharmaceuticals, human therapeutics, medical devices, and diagnostics.
The fund's limited partners include the San Francisco Employees' Retirement System, which committed $50 million.